Michael A. Boxer Sells 2,000 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thermo Fisher Scientific Stock Up 1.1 %

Shares of TMO stock opened at $575.11 on Thursday. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The firm’s fifty day moving average price is $575.03 and its two-hundred day moving average price is $531.97. The firm has a market capitalization of $219.53 billion, a P/E ratio of 36.89, a PEG ratio of 2.40 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently added to or reduced their stakes in TMO. Linden Thomas Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 8.8% during the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock worth $783,000 after acquiring an additional 125 shares in the last quarter. Avestar Capital LLC increased its stake in shares of Thermo Fisher Scientific by 15.6% in the third quarter. Avestar Capital LLC now owns 1,135 shares of the medical research company’s stock worth $575,000 after purchasing an additional 153 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Thermo Fisher Scientific by 17.7% in the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company’s stock valued at $628,000 after acquiring an additional 187 shares during the period. Steward Financial Group LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $73,000. Finally, Commonwealth Equity Services LLC lifted its position in Thermo Fisher Scientific by 0.8% during the third quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company’s stock valued at $50,467,000 after purchasing an additional 835 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Evercore ISI raised their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.